Today’s stock market focus is centered on one single sector: technology stocks. The excitement around artificial intelligence ...

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer witnessed a dramatic 45.77% surge in trading volume, reaching a staggering 11.97 billion shares. Pfizer's stock price ...

Results: JSW Infrastructure on Tuesday, July 22, posted a strong double-digit growth in its net profit and revenue for the ...

Shares of Pfizer Inc. PFE rallied 3.63% to $25.14 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and the ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...

Pfizer recently recalibrated its evaluation score, a nod to shifting trends in the market and its own financial pulse. The ...

While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...